Company intelligence / Profile preview
Orbital Therapeutics
Cambridge, Massachusetts, United Statesorbitaltx.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 2
01
Overview
Orbital Therapeutics has not yet reported clinical results. The company remains in preclinical development with a broad pipeline enabled by its proprietary platform focused on expanding the reach of RNA medicines across multiple therapeutic areas
- Therapeutic areas
- OtherMetabolic DisordersImmunologyInfectious Diseases
- Modalities
- RNA-based therapeutics (excluding RNAi/siRNA), including mRNA and other programmable RNA modalities
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Beam Therapeutics — strategic license and research collaboration for access to respective RNA technology and nonviral delivery technology. Each has exclusive fields of use within the partnership.
Beyond the preview
Go deeper on Orbital Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orbital Therapeutics.